Quantcast

Latest Eisai Stories

2014-08-29 20:22:07

DUBLIN, Ireland, August 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jjj5vs/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/jjj5vs/global_peptic ] report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and...

2014-08-29 12:24:42

PISCATAWAY, N.J., Aug. 29, 2014 /PRNewswire/ -- InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN®. InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz, Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in the United...

2014-08-20 04:20:01

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. Seeking Indication Expansion as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures Tokyo, Aug 20, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the...

2014-08-01 04:22:02

-- Conference Call and Webcast Scheduled for Today at 8:30 a.m. Eastern Time -- SAN DIEGO, Aug. 1, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2014. "We have continued to see encouraging advancements in the US commercialization of BELVIQ, including a 43% quarter-over-quarter increase in estimated total prescriptions and estimated total per week prescriptions surpassing...

2014-07-30 08:32:46

WOODCLIFF LAKE, N.J. and SAN DIEGO, July 30, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes," was recently published in the online issue of Obesity, the official peer reviewed journal of The Obesity Society. The objective of these...

2014-07-29 08:32:10

-- 2014 Nomination follows Previous Nomination in 2013 -- WOODCLIFF LAKE, N.J. and SAN DIEGO, July 29, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ(®) (lorcaserin HCl) has been nominated by the Galien Foundation and Awards Committee for the 2014 Prix Galien USA Award in the Best Pharmaceutical Agent category. BELVIQ was previously nominated for this award in 2013. "Eisai's commitment to patient care is the driving force behind our...

2014-07-11 08:24:53

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOM(TM) (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy. APTIOM(TM) is not indicated for use in patients under 18 years of age. Epilepsy is one of the most common neurological disorders and...

2014-07-10 08:27:50

-- Sales Force Increased to Approximately 600 Sales Specialists -- SAN DIEGO, July 10, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract sales representatives in its Metabolic Business Unit, increasing the sales force for BELVIQ® by 50% to approximately 600. Eisai expects this expansion of the sales force will enable them to increase their reach to approximately 92,000 physicians in...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-07-08 12:28:10

DUBLIN, July 8, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/24nt73/global) has announced the addition of the "Global Alzheimer's Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Alzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.